New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health ...

GLP-1 receptor agonists and similar drugs may protect people with opioid or alcohol use disorder from opioid overdose and ...

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will ...

A new study found a link between new popular GIP/GLP-1 receptor agonists and a reduced rate of overdose or intoxication in ...

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

These medications have been associated with a 40 percent reduction in opioid overdose and 50 percent lower rate of alcohol intoxication.

Still, more than a quarter of employers are considering adding coverage for GLP-1 drugs for weight loss in 2025 or 2026, ...

That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a ...

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies ...

A new study has revealed that people who consume Ozempic or similar medications to treat diabetic/weight-related conditions ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...